Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CLK1 | P49759 | 7/20 | 0.56 |
| ▸ | TP53 | P04637 | 1/20 | 0.49 |
| ▸ | EGFR | P00533 | 2/20 | 0.47 |
| ▸ | LCK | P06239 | 1/20 | 0.47 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.42 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.42 |
| ▸ | LPAR1 | Q92633 | 1/20 | 0.42 |
| ▸ | LPAR2 | Q9HBW0 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 2/20 | 0.41 |
| ▸ | PKM | P14618 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 2/20 | 0.41 |
| ▸ | EPAS1 | Q99814 | 1/20 | 0.39 |
| ▸ | THRB | P10828 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5315175 | 0.80 | MAPT (0.48) | CLK1EGFR | |
| SCHEMBL5334693 | 0.78 | TP53 (0.68) | CLK1TP53EGFRLCKDYRK1A | |
| SCHEMBL5641446 | 0.78 | MAPT (0.43) | LCKLPAR1LPAR2NPC1RAB9A | |
| SCHEMBL29116330 | 0.77 | MAPT (0.51) | CLK1EGFRDYRK1ADYRK1BLPAR1 | |
| SCHEMBL13434844 | 0.76 | HTT (0.51) | CLK1EGFRNPC1RAB9A | |
| SCHEMBL7892355 | 0.75 | KDR (0.52) | CLK1TP53EGFRLPAR1LPAR2 | |
| SCHEMBL13434863 | 0.75 | DYRK1A (0.48) | CLK1DYRK1ADYRK1B | |
| Hydrochloric Acid SCHEMBL7890195 | 0.74 | KDR (0.51) | CLK1TP53EGFRLPAR1LPAR2 | |
| SCHEMBL5314379 | 0.74 | EGFR (0.56) | CLK1TP53EGFRLCKDYRK1A | |
| SCHEMBL4737834 | 0.74 | FADS1 (0.60) | TP53EGFRLCKLPAR2NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070099877-A1 | N-aryl-thienopyrimidin-4-amines and analogs as activators of caspases and inducers of apoptosis and the use thereof | CYTOVIA, INC. (US) | 2007-05-03 | — | — | US | claimed |
| WO-2007056215-A9 | N-ARYL-THIENOPYRIMIDIN-4-AMINES AND THE USE THEREOF | CYTOVIA INC (US) | 2007-09-13 | — | — | WO | disclosed |
| WO-2007056215-A2 | N-ARYL-THIENOPYRIMIDIN-4-AMINES AND THE USE THEREOF | CYTOVIA, INC. (US) | 2007-05-18 | — | — | WO | disclosed |
| US-20070099877-A1 | N-aryl-thienopyrimidin-4-amines and analogs as activators of caspases and inducers of apoptosis and the use thereof | CYTOVIA, INC. (US) | 2007-05-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070099877-A1 | N-aryl-thienopyrimidin-4-amines and analogs as activators of caspases and inducers of apoptosis and the use thereof | CASP4, CASP3, API5 | CLK1 4326/4885TP53 41/4885EGFR 1226/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.